ATE312620T1 - Testverfahren für antifibrotischen wirkstoff - Google Patents

Testverfahren für antifibrotischen wirkstoff

Info

Publication number: ATE312620T1
Authority: AT; Austria
Prior art keywords: igf; culture system; fibrotic agents; tgf; beta
Prior art date: 1996-10-25

Application number

AT97949342T

Other languages

English (en)

Inventor

Jeffrey C Geesin

Anna Gosiewska

Original Assignee

Ethicon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-25

Filing date

1997-10-24

Publication date

2005-12-15

1997-10-24 Application filed by Ethicon Inc filed Critical Ethicon Inc

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE312620T1 publication Critical patent/ATE312620T1/de

Links

230000003510 anti-fibrotic effect Effects 0.000 title abstract 4
239000004480 active ingredient Substances 0.000 title 1
238000010998 test method Methods 0.000 title 1
238000000034 method Methods 0.000 abstract 5
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 3
238000003501 co-culture Methods 0.000 abstract 3
102000038460 IGF Type 2 Receptor Human genes 0.000 abstract 2
108010031792 IGF Type 2 Receptor Proteins 0.000 abstract 2
108060008539 Transglutaminase Proteins 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
238000012216 screening Methods 0.000 abstract 2
102000003601 transglutaminase Human genes 0.000 abstract 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 abstract 1
108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 abstract 1
102000002938 Thrombospondin Human genes 0.000 abstract 1
108060008245 Thrombospondin Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
239000002260 anti-inflammatory agent Substances 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
230000003828 downregulation Effects 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
210000002540 macrophage Anatomy 0.000 abstract 1
230000007246 mechanism Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
229940012957 plasmin Drugs 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Physics & Mathematics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT97949342T 1996-10-25 1997-10-24 Testverfahren für antifibrotischen wirkstoff ATE312620T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2963296P	1996-10-25	1996-10-25
PCT/US1997/019451 WO1998017304A1 (en)	1996-10-25	1997-10-24	Anti-fibrotic agent assay

Publications (1)

Publication Number	Publication Date
ATE312620T1 true ATE312620T1 (de)	2005-12-15

Family

ID=21850051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97949342T ATE312620T1 (de)	1996-10-25	1997-10-24	Testverfahren für antifibrotischen wirkstoff

Country Status (8)

Country	Link
EP (1)	EP0956036B1 (de)
JP (1)	JP2001511885A (de)
AT (1)	ATE312620T1 (de)
AU (1)	AU740052B2 (de)
CA (1)	CA2269711A1 (de)
DE (1)	DE69734894T2 (de)
ES (1)	ES2253788T3 (de)
WO (1)	WO1998017304A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1961003B (zh)	2004-03-31	2013-03-27	健泰科生物技术公司	人源化抗TGF-β抗体
EP2862867A3 (de)	2005-10-25	2015-08-05	The Johns Hopkins University	Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
EP2230252A1 (de)	2006-03-13	2010-09-22	The Johns Hopkins University	Erhöhung der endothelialen Thromboresistenz
CN101553254A (zh)	2006-10-03	2009-10-07	建新公司	TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
EP3117709B1 (de)	2010-03-12	2018-08-01	Genzyme Corporation	Kombinationstherapie zur behandlung von brustkrebs
US8956868B2 (en)	2010-12-27	2015-02-17	Lsip, Llc	Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
US9468612B2 (en)	2011-10-26	2016-10-18	Seattle Children's Hospital	Cysteamine in the treatment of fibrotic disease
US20150044178A1 (en)	2011-12-28	2015-02-12	Kyoto Prefectural Public University Corporation	Normalization of culture of corneal endothelial cells
CA2927898C (en)	2013-10-31	2021-11-16	Kyoto Prefectural Public University Corporation	Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
CN114303061A (zh) *	2019-08-15	2022-04-08	尤瓦尔·林克维奇	调节细胞外基质移动

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0466315A3 (en) *	1990-05-30	1992-07-01	Larrian Gillespie	Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
SE9101840L (sv) *	1991-06-14	1992-12-15	Kabi Pharmacia	Ny medicinsk anvaendning
US5407913A (en) *	1992-12-03	1995-04-18	Celtrix Pharmaceuticals, Inc.	Method and composition for systemic treatment of tissue injury

1997
- 1997-10-24 DE DE69734894T patent/DE69734894T2/de not_active Expired - Fee Related
- 1997-10-24 ES ES97949342T patent/ES2253788T3/es not_active Expired - Lifetime
- 1997-10-24 AT AT97949342T patent/ATE312620T1/de not_active IP Right Cessation
- 1997-10-24 AU AU68107/98A patent/AU740052B2/en not_active Expired
- 1997-10-24 EP EP97949342A patent/EP0956036B1/de not_active Expired - Lifetime
- 1997-10-24 CA CA002269711A patent/CA2269711A1/en not_active Abandoned
- 1997-10-24 WO PCT/US1997/019451 patent/WO1998017304A1/en not_active Ceased
- 1997-10-24 JP JP51969898A patent/JP2001511885A/ja active Pending

Also Published As

Publication number	Publication date
EP0956036B1 (de)	2005-12-14
JP2001511885A (ja)	2001-08-14
CA2269711A1 (en)	1998-04-30
AU740052B2 (en)	2001-10-25
EP0956036A1 (de)	1999-11-17
EP0956036A4 (de)	2001-10-10
DE69734894D1 (de)	2006-01-19
DE69734894T2 (de)	2006-07-20
AU6810798A (en)	1998-05-15
ES2253788T3 (es)	2006-06-01
WO1998017304A1 (en)	1998-04-30

Legal Events

Date

Code

Title

Description

2006-09-15

UEP

Publication of translation of european patent specification

Ref document number: 0956036

Country of ref document: EP

2008-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
Hwang et al.	2019	Variable osteogenic performance of MC3T3-E1 subclones impacts their utility as models of osteoblast biology
DE69734894D1 (de)	2006-01-19	Testverfahren für antifibrotischen wirkstoff
DE69841164D1 (de)	2009-10-29	Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
Agís-Balboa et al.	2006	Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis
Minnaard et al.	2005	Skeletal muscle wasting and contractile performance in septic rats
EP0747656A3 (de)	1998-11-25	Verfahren und Vorrichtung zum Testen von Raketen
ATE284900T1 (de)	2005-01-15	Spezifische antikörper für dendritische zellen
DE69632681D1 (de)	2004-07-15	Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
Rogers et al.	1995	Cross‐validation of the five‐factor interpretive model of the suicide opinion questionnaire
TR199700482A2 (xx)	1998-01-21	LC132 (Opioid benzeri) resept�r fonksiyonunun mod�lasyonu.
DK0782706T3 (da)	2001-03-19	Testmetode
Yuan et al.	2006	Proteomic profiling of regionalized proteins in rat epididymis indicates consistency between specialized distribution and protein functions
Sonnet et al.	1999	Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves’ disease
Lacampagne et al.	2000	Two mechanisms for termination of individual Ca2+ sparks in skeletal muscle
ATE415487T1 (de)	2008-12-15	Biologisches testverfahren für thyroid stimulierende antikörper
Levy et al.	1979	Audience size and likelihood and intensity of response during a humorous movie
Evans et al.	1985	AUGMENTATION OF ANDROGEN‐RECEPTOR BINDING IN VITRO: STUDIES IN NORMALS AND PATIENTS WITH ANDROGEN INSENSITIVITY
Kol et al.	1999	Ovarian interleukin-1 receptor antagonist in rats: gene expression, cellular localization, cyclic variation, and hormonal regulation of a potential determinant of interleukin-1 action
MX9302549A (es)	1994-07-29	Proteina receptora especifica para la region csvt cg de la trombospondina y metodo para su purificacion y caracterizacion.
Palkovits et al.	2009	Acoustic stress activates tuberoinfundibular peptide of 39 residues neurons in the rat brain
GR3034891T3 (en)	2001-02-28	Method and kit for predicting the therapeutic response of a drug against a malignant tumour
SE9602234D0 (sv)	1996-06-06	A novel diagnostic method utilizing ECP, and reagents to be used in the methods
Dreger et al.	2005	Analysis of the dorsal spinal cord synaptic architecture by combined proteome analysis and in situ hybridization
Kamins et al.	1987	THE EFFECT OF FRAMING AND ADVERTISING SEQUENCING ON ATTITUDE CONSISTENCY AND BEHAVIORAL INTENTIONS.
Skarlatos et al.	2001	Memorization of young people under loud pink noise of short duration